Skip to main content
NCBI home page
Cytotechnology logoLink to Cytotechnology
. 2003 Mar;41(2-3):111–131. doi: 10.1023/A:1024822722285

Isolation and therapeutic potential of human haemopoietic stem cells

Andrew D Clark 1,2, Heather G Jørgensen 3, Joanne Mountford 3, Tessa L Holyoake 1,✉
PMCID: PMC3466700  PMID: 19002948

Abstract

The haemopoietic stem cell (HSC) has long been regarded as an archetypal, tissue specific, stem cell, capable of completely regenerating haemopoiesis after myeloablation. It has proved relatively easy to harvest HSC, from bone marrow or peripheral blood. In turn, isolation of these cells has allowed therapeutic stem cell transplantation protocols to be developed, that capitalise on their prodigious self renewal and proliferative capabilities. Ex vivo approaches have been described to isolate, genetically manipulateand expand pluripotent stem cell subsets. These techniques have been crucial to the development of gene therapy, and may allow adults to enjoy the potential advantages of cord blood transplantation. Recently, huge conceptual changes have occurred in stem cell biology. In particular, the dogma that, in adults, stem cells are exclusively tissue restricted has been questioned and there is great excitement surrounding the potential plasticity of these cells, with the profound implications that this has, for developing novel cellular therapies. Mesenchymal stem cells, multipotent adult progenitor cells and embryonic stem cells are potential sources of cells for transplantation purposes. These cells may be directed toproduce HSC, in vitro and in the future may be used for therapeutic, or drug development, purposes.

Keywords: embryonic stem cells, gene therapy, haemopoietic stem cells, MAPC, mesenchymal stem cells, stem cell transplantation

Full Text

The Full Text of this article is available as a PDF (250.4 KB).

References

  1. Abramson S, Miller RG, Phillips RA. The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J Exp Med. 1977;145:1567–1579. doi: 10.1084/jem.145.6.1567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–2413. doi: 10.1126/science.1070104. [DOI] [PubMed] [Google Scholar]
  3. Alcorn MJ, Farrell E, Barr J, Pearson C, Green R, Holyoake T. The number of CD34+ cells mobilized into the peripheral blood can predict the quality of subsequent collections. J Hematother Stem Cell Res. 2000;9:89–93. doi: 10.1089/152581600319667. [DOI] [PubMed] [Google Scholar]
  4. Alcorn MJ, Holyoake TL. Ex vivo expansion of haemopoietic progenitor cells. Blood Rev. 1996;10:167–176. doi: 10.1016/s0268-960x(96)90023-5. [DOI] [PubMed] [Google Scholar]
  5. Almeida-Porada G, Brown RL, MacKintosh FR, Zanjani ED. Evaluation of serum-free culture conditions able to support the ex vivo expansion and engraftment of human hematopoietic stem cells in the human-to-sheep xenograft model. J Hematother Stem Cell Res. 2000;9:683–693. doi: 10.1089/15258160050196722. [DOI] [PubMed] [Google Scholar]
  6. Andrews RG, Briddell RA, Knitter GH, Opie T, Bronsden M, Myerson D, Appelbaum FR, McNiece IK. In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons enhanced circulation of progenitor cells. Blood. 1994;84:800–810. [PubMed] [Google Scholar]
  7. Aversa F, Velardi A, Tabilio A, Reisner Y, Martelli MF. Haploidentical stem cell transplantation in leukemia. Blood Rev. 2001;15:111–119. doi: 10.1054/blre.2001.0157. [DOI] [PubMed] [Google Scholar]
  8. Bai L, Kon K, Tatsumi M, Ito H, Hayashi S, Brautigam M. A human B-cell CLL model established by transplantation of JOK-1 cells into SCID mice and an anti-leukemia efficacy of fludarabine phosphate. Oncol Rep. 2000;7:33–38. doi: 10.3892/or.7.1.33. [DOI] [PubMed] [Google Scholar]
  9. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood. 1998;91:3582–3592. [PubMed] [Google Scholar]
  10. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42–48. doi: 10.1016/s0301-472x(01)00769-x. [DOI] [PubMed] [Google Scholar]
  11. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA. 1992;89:2804–2808. doi: 10.1073/pnas.89.7.2804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bhardwaj G, Murdoch B, Wu D, Baker DP, Williams KP, Chadwick K, Ling LE, Karanu FN, Bhatia M. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol. 2001;2:172–180. doi: 10.1038/84282. [DOI] [PubMed] [Google Scholar]
  13. Bhatia M. AC133 expression in human stem cells. Leukemia. 2001;15:1685–1688. doi: 10.1038/sj.leu.2402255. [DOI] [PubMed] [Google Scholar]
  14. Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med. 1998;4:1038–1045. doi: 10.1038/2023. [DOI] [PubMed] [Google Scholar]
  15. Bhatia M, Bonnet D, Wu D, Murdoch B, Wrana J, Gallacher L, Dick JE. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J Exp Med. 1999;189:1139–1148. doi: 10.1084/jem.189.7.1139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA. 1997;94:5320–5325. doi: 10.1073/pnas.94.10.5320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Bhatia R, McGlave PB, Miller JS, Wissink S, Lin WN, Verfaillie CM. A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium. Exp Hematol. 1997;25:980–991. [PubMed] [Google Scholar]
  18. Bittner RE, Schofer C, Weipoltshammer K, Ivanova S, Streubel B, Hauser E, Freilinger M, Hoger H, Elbe-Burger A, Wachtler F. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat Embryol (Berl) 1999;199:391–396. doi: 10.1007/s004290050237. [DOI] [PubMed] [Google Scholar]
  19. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737. doi: 10.1038/nm0797-730. [DOI] [PubMed] [Google Scholar]
  20. Bradford GB, Williams B, Rossi R, Bertoncello I. Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Exp Hematol. 1997;25:445–453. [PubMed] [Google Scholar]
  21. Breems DA, Blokland EA, Siebel KE, Mayen AE, Engels LJ, Ploemacher RE. Stroma-contact prevents loss of hematopoietic stem cell quality during ex vivo expansion of CD34+ mobilized peripheral blood stem cells. Blood. 1998;91:111–117. [PubMed] [Google Scholar]
  22. Brummendorf TH, Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ, Eaves AC, Lansdorp PM. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood. 2000;95:1883–1890. [PubMed] [Google Scholar]
  23. Brummendorf TH, Rufer N, Baerlocher GM, Roosnek E, Lansdorp PM. Limited telomere shortening in hematopoietic stem cells after transplantation. Ann N Y Acad Sci. 2001;938:1–7. doi: 10.1111/j.1749-6632.2001.tb03568.x. [DOI] [PubMed] [Google Scholar]
  24. Brummendorf TH, Rufer N, Holyoake TL, Maciejewski J, Barnett MJ, Eaves CJ, Eaves AC, Young N, Lansdorp PM. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann N Y Acad Sci. 2001;938:293–303. doi: 10.1111/j.1749-6632.2001.tb03598.x. [DOI] [PubMed] [Google Scholar]
  25. Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells. 2002;20:11–20. doi: 10.1002/stem.200011. [DOI] [PubMed] [Google Scholar]
  26. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure? Blood. 2002;99:768–784. doi: 10.1182/blood.v99.3.768. [DOI] [PubMed] [Google Scholar]
  27. Cashman J, Clark-Lewis I, Eaves A, Eaves C. Stromal derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. Blood. 2002;99:792–799. doi: 10.1182/blood.v99.3.792. [DOI] [PubMed] [Google Scholar]
  28. Castro RF, Jackson KA, Goodell MA, Robertson CS, Liu H, Shine HD. Failure of bone marrow cells to transdifferentiate into neural cells in vivo. Science. 2002;297:1299. doi: 10.1126/science.297.5585.1299. [DOI] [PubMed] [Google Scholar]
  29. Caterson EJ, Nesti LJ, Danielson KG, Tuan RS. Human marrow-derived mesenchymal progenitor cells: isolation, culture expansion, and analysis of differentiation. Mol Biotechnol. 2002;20:245–256. doi: 10.1385/MB:20:3:245. [DOI] [PubMed] [Google Scholar]
  30. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669–672. doi: 10.1126/science.288.5466.669. [DOI] [PubMed] [Google Scholar]
  31. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–1078. doi: 10.1182/blood.v99.3.1071. [DOI] [PubMed] [Google Scholar]
  32. Charbord P, Oostendorp R, Pang W, Herault O, Noel F, Tsuji T, Dzierzak E, Peault B. Comparative study of stromal cell lines derived from embryonic, fetal, and postnatal mouse bloodforming tissues. Exp Hematol. 2002;30:1202. doi: 10.1016/s0301-472x(02)00895-0. [DOI] [PubMed] [Google Scholar]
  33. Chatta GS, Dale DC. Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. Drugs Aging. 1996;9:37–47. doi: 10.2165/00002512-199609010-00004. [DOI] [PubMed] [Google Scholar]
  34. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, Scadden DT. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science. 2000;287:1804–1808. doi: 10.1126/science.287.5459.1804. [DOI] [PubMed] [Google Scholar]
  35. Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci USA. 1999;96:3120–3125. doi: 10.1073/pnas.96.6.3120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS, Barrett AJ. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234–3241. [PubMed] [Google Scholar]
  37. Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE, Harley CB, Lansdorp PM. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells. 1996;14:239–248. doi: 10.1002/stem.140239. [DOI] [PubMed] [Google Scholar]
  38. Civin CI, Almeida-Porada G, Lee MJ, Olweus J, Terstappen LW, Zanjani ED. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood. 1996;88:4102–4109. [PubMed] [Google Scholar]
  39. Corti S, Strazzer S, Del Bo R, Salani S, Bossolasco P, Fortunato F, Locatelli F, Soligo D, Moggio M, Ciscato P, Prelle A, Borsotti C, Bresolin N, Scarlato G, Comi GP. A subpopulation of murine bone marrow cells fully differentiates along the myogenic pathway and participates in muscle repair in the mdx dystrophic mouse. Exp Cell Res. 2002;277:74–85. doi: 10.1006/excr.2002.5543. [DOI] [PubMed] [Google Scholar]
  40. Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med. 1993;177:1331–1342. doi: 10.1084/jem.177.5.1331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Dao MA, Shah AJ, Crooks GM, Nolta JA. Engraftment and retroviral marking of CD34+ and CD34+CD38– human hematopoietic progenitors assessed in immune-deficient mice. Blood. 1998;91:1243–55. [PubMed] [Google Scholar]
  42. Dennis JE, Carbillet JP, Caplan AI, Charbord P. The STRO-1+ marrow cell population is multipotential. Cells Tissues Organs. 2002;170:73–82. doi: 10.1159/000046182. [DOI] [PubMed] [Google Scholar]
  43. Dexter TM, Moore MA, Sheridan AP. Maintenance of hemopoietic stem cells and production of differentiated progeny in allogeneic and semiallogeneic bone marrow chimeras in vitro. J Exp Med. 1977;145:1612–1616. doi: 10.1084/jem.145.6.1612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Dick JE. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol. 1996;8:197–206. doi: 10.1006/smim.1996.0025. [DOI] [PubMed] [Google Scholar]
  45. Dick JE, Sirard C, Pflumio F, Lapidot T. Murine models of normal and neoplastic human haematopoiesis. Cancer Surv. 1992;15:161–181. [PubMed] [Google Scholar]
  46. Effros RB, Globerson A. Hematopoietic cells and replicative senescence. Exp Gerontol. 2002;37:191–196. doi: 10.1016/s0531-5565(01)00183-8. [DOI] [PubMed] [Google Scholar]
  47. Engelhardt M, Finke J. Does telomere shortening count? Blood. 2001;98:888–890. doi: 10.1182/blood.v98.3.888. [DOI] [PubMed] [Google Scholar]
  48. Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MA. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood. 1997;90:182–193. [PubMed] [Google Scholar]
  49. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 2000;109:235–242. doi: 10.1046/j.1365-2141.2000.01986.x. [DOI] [PubMed] [Google Scholar]
  50. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:154–156. doi: 10.1038/292154a0. [DOI] [PubMed] [Google Scholar]
  51. Facon T, Harousseau JL, Maloisel F, Attal M, Odriozola J, Alegre A, Schroyens W, Hulin C, Schots R, Marin P, Guilhot F, Granena A, DeWaele M, Pigneux A, Meresse V, Clark P, Reiffers J. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized, controlled trial. Blood. 1999;94:1218–1225. [PubMed] [Google Scholar]
  52. Flake AW. In utero transplantation of haemopoietic stem cells. Best Pract Res Clin Haematol. 2001;14:671–683. doi: 10.1053/beha.2001.0166. [DOI] [PubMed] [Google Scholar]
  53. Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation. A status report. Jama. 1997;278:932–937. [PubMed] [Google Scholar]
  54. Flake AW, Zanjani ED. In utero transplantation for thalassemia. Ann N Y Acad Sci. 1998;850:300–311. doi: 10.1111/j.1749-6632.1998.tb10487.x. [DOI] [PubMed] [Google Scholar]
  55. Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation: Ontogenic opportunities and biologic barriers. Blood. 1999;94:2179–2191. [PubMed] [Google Scholar]
  56. Forbes SJ, Poulsom R, Wright NA. Hepatic and renal differentiation from blood-borne stem cells. Gene Ther. 2002;9:625–630. doi: 10.1038/sj.gt.3301720. [DOI] [PubMed] [Google Scholar]
  57. Forbes SJ, Vig P, Poulsom R, Wright NA, Alison MR. Adult stem cell plasticity: New pathways of tissue regeneration become visible. Clin Sci (Lond) 2002;103:355–369. doi: 10.1042/cs1030355. [DOI] [PubMed] [Google Scholar]
  58. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3128–3135. doi: 10.1200/JCO.1999.17.10.3128. [DOI] [PubMed] [Google Scholar]
  59. Gallacher L, Murdoch B, Wu DM, Karanu FN, Keeney M, Bhatia M. Isolation and characterization of human CD34(–)Lin(–) and CD34(+)Lin(–) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood. 2000;95:2813–2820. [PubMed] [Google Scholar]
  60. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, Lill M, Chap L, Jones R, Wiers MD, Sheridan WP, McNiece IK. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood. 1997;90:2939–2951. [PubMed] [Google Scholar]
  61. Gluckman E. Hematopoietic stem-cell transplants using umbilical-cord blood. N Engl J Med. 2001;344:1860–1861. doi: 10.1056/NEJM200106143442410. [DOI] [PubMed] [Google Scholar]
  62. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, Ortega J, Souillet G, Ferreira E, Laporte JP, Fernandez M, Chastang C. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337:373–381. doi: 10.1056/NEJM199708073370602. [DOI] [PubMed] [Google Scholar]
  63. Godin I, Cumano A. The hare and the tortoise: An embryonic haematopoietic race. Nat Rev Immunol. 2002;2:593–604. doi: 10.1038/nri857. [DOI] [PubMed] [Google Scholar]
  64. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302–1311. doi: 10.1182/blood.v98.5.1302. [DOI] [PubMed] [Google Scholar]
  65. Goodell MA. Introduction: Focus on hematology. CD34(+) or CD34(–): does it really matter? Blood. 1999;94:2545–2547. [PubMed] [Google Scholar]
  66. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G, Grupp SA, Sieff CA, Mulligan RC, Johnson RP. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997;3:1337–1345. doi: 10.1038/nm1297-1337. [DOI] [PubMed] [Google Scholar]
  67. Graf T. Differentiation plasticity of hematopoietic cells. Blood. 2002;99:3089–3101. doi: 10.1182/blood.v99.9.3089. [DOI] [PubMed] [Google Scholar]
  68. Graham GJ, Pragnell IB. The haemopoietic stem cell: Properties and control mechanisms. Semin Cell Biol. 1992;3:423–434. doi: 10.1016/1043-4682(92)90013-l. [DOI] [PubMed] [Google Scholar]
  69. Graham GJ, Wright EG. Haemopoietic stem cells: Their heterogeneity and regulation. Int J Exp Pathol. 1997;78:197–218. doi: 10.1046/j.1365-2613.1997.270361.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–325. doi: 10.1182/blood.v99.1.319. [DOI] [PubMed] [Google Scholar]
  71. Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, Byrne BJ, Vaught T, Spoerri PE, Peck AB, Scott EW. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med. 2002;8:607–612. doi: 10.1038/nm0602-607. [DOI] [PubMed] [Google Scholar]
  72. Gratwohl A, Passweg J, Gerber I, Tyndall A. Stem cell transplantation for autoimmune diseases. Best Pract Res Clin Haematol. 2001;14:755–776. doi: 10.1053/beha.2001.0171. [DOI] [PubMed] [Google Scholar]
  73. Greider CW. Mammalian telomere dynamics: Healing, fragmentation shortening and stabilization. Curr Opin Genet Dev. 1994;4:203–211. doi: 10.1016/s0959-437x(05)80046-2. [DOI] [PubMed] [Google Scholar]
  74. Grompe M. Adult versus Embryonic Stem Cells: It's Still a Tie. Mol Ther. 2002;6:303. doi: 10.1006/mthe.2002.0687. [DOI] [PubMed] [Google Scholar]
  75. Gunzburg W, Hemiston T, Seymour L (eds) (2002) Gene transfer and cell based therapies. Current opinion in molecular therapeutics 4: 281–407.
  76. Hackney JA, Charbord P, Brunk BP, Stoeckert CJ, Lemischka IR, Moore KA. A molecular profile of a hematopoietic stem cell niche. Proc Natl Acad Sci USA. 2002;99:13061–13066. doi: 10.1073/pnas.192124499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Hall FL, Han B, Kundu RK, Yee A, Nimni ME, Gordon EM. Phenotypic differentiation of TGF-beta1-responsive pluripotent premesenchymal prehematopoietic progenitor (P4 stem) cells from murine bone marrow. J Hematother Stem Cell Res. 2001;10:261–271. doi: 10.1089/15258160151134962. [DOI] [PubMed] [Google Scholar]
  78. Hao QL, Thiemann FT, Petersen D, Smogorzewska EM, Crooks GM. Extended long-term culture reveals a highly quiescent and primitive human hematopoietic progenitor population. Blood. 1996;88:3306–3313. [PubMed] [Google Scholar]
  79. Harrison DE. Mouse erythropoietic stem cell lines function normally 100 months: loss related to number of transplantations. Mech Ageing Dev. 1979;9:427–433. doi: 10.1016/0047-6374(79)90083-6. [DOI] [PubMed] [Google Scholar]
  80. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L, Hendrikx J, Hackett NR, Crystal RG, Moore MA, Werb Z, Lyden D, Rafii S. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med. 2002;8:841–849. doi: 10.1038/nm740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Hayashi S, Peranteau WH, Shaaban AF, Flake AW. Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion. Blood. 2002;100:804–812. doi: 10.1182/blood-2002-01-0016. [DOI] [PubMed] [Google Scholar]
  82. Hayflick L. Aging, longevity, and immortality in vitro. Exp Gerontol. 1992;27:363–368. doi: 10.1016/0531-5565(92)90066-9. [DOI] [PubMed] [Google Scholar]
  83. Hayward A, Ambruso D, Battaglia F, Donlon T, Eddelman K, Giller R, Hobbins J, Hsia YE, Quinones R, Shpall E, Trachtenberg E, Giardina P. Microchimerism and tolerance following intrauterine transplantation and transfusion for alphathalassemia-1. Fetal Diagn Ther. 1998;13:8–14. doi: 10.1159/000020793. [DOI] [PubMed] [Google Scholar]
  84. Heike T, Nakahata T. Ex vivo expansion of hematopoietic stem cells by cytokines. Biochim Biophys Acta. 2002;1592:313–321. doi: 10.1016/s0167-4889(02)00324-5. [DOI] [PubMed] [Google Scholar]
  85. Henslee-Downey PJ. Allogeneic transplantation across major HLA barriers. Best Pract Res Clin Haematol. 2001;14:741–754. doi: 10.1053/beha.2001.0170. [DOI] [PubMed] [Google Scholar]
  86. Hess DA, Levac KD, Karanu FN, Rosu-Myles M, White MJ, Gallacher L, Murdoch B, Keeney M, Ottowski P, Foley R, Chin-Yee I & Bhatia M (2002) Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colonystimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor. Blood 100: 869–878. [DOI] [PubMed]
  87. Heyworth C, Pearson S, May G, Enver T. Transcription factor-mediated lineage switching reveals plasticity in primary committed progenitor cells. Embo J. 2002;21:3770–3781. doi: 10.1093/emboj/cdf368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Hirschi KK, Goodell MA. Hematopoietic, vascular and cardiac fates of bone marrow-derived stem cells. Gene Ther. 2002;9:648–652. doi: 10.1038/sj.gt.3301722. [DOI] [PubMed] [Google Scholar]
  89. Hole N, Graham GJ. Use of embryonal stem cells in studies of molecular haemopoiesis. Baillieres Clin Haematol. 1997;10:467–483. doi: 10.1016/s0950-3536(97)80021-2. [DOI] [PubMed] [Google Scholar]
  90. Hole N, Graham GJ, Menzel U, Ansell JD. A limited temporal window for the derivation of multilineage repopulating hematopoietic progenitors during embryonal stem cell differentiation in vitro. Blood. 1996;88:1266–1276. [PubMed] [Google Scholar]
  91. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94:2056–2064. [PubMed] [Google Scholar]
  92. Holyoake TL. Cytokines at the research-clinical interface: Potential applications. Blood Rev. 1996;10:189–200. doi: 10.1016/s0268-960x(96)90026-0. [DOI] [PubMed] [Google Scholar]
  93. Holyoake TL, Alcorn MJ, Richmond L, Farrell E, Pearson C, Green R, Dunlop DJ, Fitzsimons E, Pragnell IB, Franklin IM. CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens. Bone Marrow Transplant. 1997;19:1095–1101. doi: 10.1038/sj.bmt.1700799. [DOI] [PubMed] [Google Scholar]
  94. Holyoake TL, Freshney MG, Konwalinka G, Haun M, Petzer A, Fitzsimons E, Lucie NP, Wright EG, Pragnell IB. Mixed colony formation in vitro by the heterogeneous compartment of multipotential progenitors in human bone marrow. Leukemia. 1993;7:207–213. [PubMed] [Google Scholar]
  95. Holyoake TL, Freshney MG, McNair L, Parker AN, McKay PJ, Steward WP, Fitzsimons E, Graham GJ, Pragnell IB. Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow. Blood. 1996;87:4589–4595. [PubMed] [Google Scholar]
  96. Holyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, Laird C, Eaves AC, Eaves CJ. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with upregulation of expression of interleukin-3. Blood. 2001;97:720–728. doi: 10.1182/blood.v97.3.720. [DOI] [PubMed] [Google Scholar]
  97. Holyoake TL, Nicolini FE, Eaves CJ. Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow. Exp Hematol. 1999;27:1418–1427. doi: 10.1016/s0301-472x(99)00078-8. [DOI] [PubMed] [Google Scholar]
  98. Horwitz EM. Marrow mesenchymal cell transplantation for genetic disorders of bone. Cytotherapy. 2001;3:399–401. doi: 10.1080/146532401753277562. [DOI] [PubMed] [Google Scholar]
  99. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99:8932–8937. doi: 10.1073/pnas.132252399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5:309–313. doi: 10.1038/6529. [DOI] [PubMed] [Google Scholar]
  101. Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, McCarville ME, Orchard PJ, Pyeritz RE, Brenner MK. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001;97:1227–1231. doi: 10.1182/blood.v97.5.1227. [DOI] [PubMed] [Google Scholar]
  102. Ishikawa F, Livingston AG, Wingard JR, Nishikawa S, Ogawa M. An assay for long-term engrafting human hematopoietic cells based on newborn NOD/SCID/beta2-microglobulin(null) mice. Exp Hematol. 2002;30:488–494. doi: 10.1016/s0301-472x(02)00784-1. [DOI] [PubMed] [Google Scholar]
  103. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175–3182. doi: 10.1182/blood-2001-12-0207. [DOI] [PubMed] [Google Scholar]
  104. Ito T, Tajima F, Ogawa M. Developmental changes of CD34 expression by murine hematopoietic stem cells. Exp Hematol. 2000;28:1269–1273. doi: 10.1016/s0301-472x(00)00535-x. [DOI] [PubMed] [Google Scholar]
  105. Jackson KA, Mi T, Goodell MA. Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci USA. 1999;96:14482–14486. doi: 10.1073/pnas.96.25.14482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41–49. doi: 10.1038/nature00870. [DOI] [PubMed] [Google Scholar]
  107. Jones DR, Bui TH, Anderson EM, Ek S, Liu D, Ringden O, Westgren M. In utero haematopoietic stem cell transplantation: current perspectives and future potential. Bone Marrow Transplant. 1996;18:831–837. [PubMed] [Google Scholar]
  108. Jordan CT, Lemischka IR. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev. 1990;4:220–232. doi: 10.1101/gad.4.2.220. [DOI] [PubMed] [Google Scholar]
  109. Jørgensen H, Allan E, Graham S, Richmond L, Godden J, Holyoake T. Will drug combinations effectively eradicate quiescent leukaemic stem cells in Chronic Myeloid Leukaemia. Experimental Hematology. 2002;30:73. [Google Scholar]
  110. Jørgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. Alpha-1-acid glycoprotein expressed in the plasma of chronic myeloid leukaemia patients does not mediate significant in vitro resistance to STI571 (Glivec) Blood. 2002;99:713–715. doi: 10.1182/blood.v99.2.713. [DOI] [PubMed] [Google Scholar]
  111. Jørgensen HG, Elliott MA, Paterson S, Holyoake TL, Smith KD. Further observations on the debated ability of AGP to bind imatinib. Blood. 2002;100:368–369. [Google Scholar]
  112. Kawashima I, Zanjani ED, Almaida-Porada G, Flake AW, Zeng H, Ogawa M. CD34+ human marrow cells that express low levels of Kit protein are enriched for long-term marrowengrafting cells. Blood. 1996;87:4136–4142. [PubMed] [Google Scholar]
  113. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257–261. doi: 10.1038/73464. [DOI] [PubMed] [Google Scholar]
  114. Keller G, Snodgrass HR. Human embryonic stem cells: The future is now. Nat Med. 1999;5:151–152. doi: 10.1038/5512. [DOI] [PubMed] [Google Scholar]
  115. Keller G, Snodgrass R. Life span of multipotential hematopoietic stem cells in vivo. J Exp Med. 1990;171:1407–1418. doi: 10.1084/jem.171.5.1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Keller GM. In vitro differentiation of embryonic stem cells. Curr Opin Cell Biol. 1995;7:862–869. doi: 10.1016/0955-0674(95)80071-9. [DOI] [PubMed] [Google Scholar]
  117. Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sanchez-Pernaute R, Bankiewicz K, McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418:50–56. doi: 10.1038/nature00900. [DOI] [PubMed] [Google Scholar]
  118. Koc ON, Lazarus HM. Mesenchymal stem cells: Heading into the clinic. Bone Marrow Transplant. 2001;27:235–239. doi: 10.1038/sj.bmt.1702791. [DOI] [PubMed] [Google Scholar]
  119. Kojika S, Griffin JD. Notch receptors and hematopoiesis. Exp Hematol. 2001;29:1041–1052. doi: 10.1016/s0301-472x(01)00676-2. [DOI] [PubMed] [Google Scholar]
  120. Kollet O, Peled A, Byk T, Ben-Hur H, Greiner D, Shultz L, Lapidot T. beta2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function. Blood. 2000;95:3102–3105. [PubMed] [Google Scholar]
  121. Korbling M. Peripheral blood stem cells: A novel source for allogeneic transplantation. Oncologist. 1997;2:104–113. [PubMed] [Google Scholar]
  122. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: Does the source of hematopoietic stem cells matter? Blood. 2001;98:2900–2908. doi: 10.1182/blood.v98.10.2900. [DOI] [PubMed] [Google Scholar]
  123. Korbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med. 2002;346:738–746. doi: 10.1056/NEJMoa3461002. [DOI] [PubMed] [Google Scholar]
  124. Krause DS. Plasticity of marrow-derived stem cells. Gene Ther. 2002;9:754–758. doi: 10.1038/sj.gt.3301760. [DOI] [PubMed] [Google Scholar]
  125. Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, Wang X, Finegold M, Weissman IL, Grompe M. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6:1229–1234. doi: 10.1038/81326. [DOI] [PubMed] [Google Scholar]
  126. Lane TA, Ho AD, Bashey A, Peterson S, Young D, Law P. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage-and granulocytecolony-stimulating factors. Transfusion. 1999;39:39–47. doi: 10.1046/j.1537-2995.1999.39199116893.x. [DOI] [PubMed] [Google Scholar]
  127. Larochelle A, Vormoor J, Hanenberg H, Wang JC, Bhatia M, Lapidot T, Moritz T, Murdoch B, Xiao XL, Kato I, Williams DA, Dick JE. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy. Nat Med. 1996;2:1329–1337. doi: 10.1038/nm1296-1329. [DOI] [PubMed] [Google Scholar]
  128. Lataillade JJ, Clay D, Bourin P, Herodin F, Dupuy C, Jasmin C, Bousse-Kerdiles MC. Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: Evidence for an autocrine/paracrine mechanism. Blood. 2002;99:1117–1129. doi: 10.1182/blood.v99.4.1117. [DOI] [PubMed] [Google Scholar]
  129. Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, Romquin N, Clay D, Smadja-Joffe F, Praloran V, Dupriez B, Demory JL, Jasmin C, Martyre MC. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996;88:4534–4546. [PubMed] [Google Scholar]
  130. Lee HW, Blasco MA, Gottlieb GJ, Horner JW, 2nd Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature. 1998;392:569–574. doi: 10.1038/33345. [DOI] [PubMed] [Google Scholar]
  131. Lemischka I. Stem cell dogmas in the genomics era. Rev Clin Exp Hematol. 2001;5:15–25. doi: 10.1046/j.1468-0734.2001.00030.x. [DOI] [PubMed] [Google Scholar]
  132. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001;98:1289–1297. doi: 10.1182/blood.v98.5.1289. [DOI] [PubMed] [Google Scholar]
  133. Liu F, Poursine-Laurent J, Link DC. The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin-8 but not flt-3 ligand. Blood. 1997;90:2522–2528. [PubMed] [Google Scholar]
  134. Liu F, Poursine-Laurent J, Link DC. Expression of the GCSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF. Blood. 2000;95:3025–3031. [PubMed] [Google Scholar]
  135. Loeuillet C, Bernard G, Remy-Martin J, Saas P, Herve P, Douay L, Chalmers D. Distinct hematopoietic support by two human stromal cell lines. Exp Hematol. 2001;29:736–745. doi: 10.1016/s0301-472x(01)00644-0. [DOI] [PubMed] [Google Scholar]
  136. Mackenzie TC, Shaaban AF, Radu A, Flake AW. Engraftment of bone marrow and fetal liver cells after in utero transplantation in MDX mice. J Pediatr Surg. 2002;37:1058–1064. doi: 10.1053/jpsu.2002.33844. [DOI] [PubMed] [Google Scholar]
  137. Mahmud N, Devine SM, Weller KP, Parmar S, Sturgeon C, Nelson MC, Hewett T, Hoffman R. The relative quiescence of hematopoietic stem cells in nonhuman primates. Blood. 2001;97:3061–3068. doi: 10.1182/blood.v97.10.3061. [DOI] [PubMed] [Google Scholar]
  138. Maris M, Woolfrey A, McSweeney PA, Sandmaier BM, Nash RA, Georges G, Maloney DG, Molina A, Chauncey T, Yu C, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R. Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21st century. Front Biosci. 2001;6:G13–G16. doi: 10.2741/maris. [DOI] [PubMed] [Google Scholar]
  139. Marshall E. The business of stem cells. Science. 2000;287:1419–1421. doi: 10.1126/science.287.5457.1419. [DOI] [PubMed] [Google Scholar]
  140. Marshall E. Clinical research. Gene therapy a suspect in leukemia-like disease. Science. 2002;298:34–35. doi: 10.1126/science.298.5591.34. [DOI] [PubMed] [Google Scholar]
  141. Marshall E. Gene therapy. What to do when clear success comes with an unclear risk? Science. 2002;298:510–511. doi: 10.1126/science.298.5593.510. [DOI] [PubMed] [Google Scholar]
  142. Mathioudakis G, Storb R, McSweeney PA, Torok-Storb B, Lansdorp PM, Brummendorf T, Gass MJ, Bryant EM, Storek J, Flowers ME, Gooley T, Nash RA. Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients. Blood. 2000;96:3991–3994. [PubMed] [Google Scholar]
  143. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 1996;88:3223–3229. [PubMed] [Google Scholar]
  144. McKay R. Building animals from stem cells. Ann N Y Acad Sci. 2002;961:44. doi: 10.1111/j.1749-6632.2002.tb03045.x. [DOI] [PubMed] [Google Scholar]
  145. McKinney-Freeman SL, Jackson KA, Camargo FD, Ferrari G, Mavilio F, Goodell MA. Muscle-derived hematopoietic stem cells are hematopoietic in origin. Proc Natl Acad Sci USA. 2002;99:1341–1346. doi: 10.1073/pnas.032438799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning blood into brain: Cells bearing neuronal antigens generated in vivo from bone marrow. Science. 2000;290:1779–1782. doi: 10.1126/science.290.5497.1779. [DOI] [PubMed] [Google Scholar]
  147. Migliaccio AR, Adamson JW, Stevens CE, Dobrila NL, Carrier CM, Rubinstein P. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: Graft progenitor cell content is a better predictor than nucleated cell quantity. Blood. 2000;96:2717–2722. [PubMed] [Google Scholar]
  148. Milner LA, Bigas A. Notch as a mediator of cell fate determination in hematopoiesis: Evidence and speculation. Blood. 1999;93:2431–2448. [PubMed] [Google Scholar]
  149. Molineux G, Migdalska A, Szmitkowski M, Zsebo K, Dexter TM. The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocyte colony-stimulating factor. Blood. 1991;78:961–966. [PubMed] [Google Scholar]
  150. Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood. 1990;76:2153–2158. [PubMed] [Google Scholar]
  151. Monahan PE, White IG. Hemophilia gene therapy: Update. Curr Opin Hematol. 2002;9:430–436. doi: 10.1097/00062752-200209000-00007. [DOI] [PubMed] [Google Scholar]
  152. Moore KA, Ema H, Lemischka IR. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood. 1997;89:4337–4347. [PubMed] [Google Scholar]
  153. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, Rafii S. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1: VEGF, and angiopoietin-1. Ann N Y Acad Sci. 2001;938:36–45. doi: 10.1111/j.1749-6632.2001.tb03572.x. [DOI] [PubMed] [Google Scholar]
  154. Morrison SJ, Prowse KR, Ho P, Weissman IL. Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity. 1996;5:207–216. doi: 10.1016/s1074-7613(00)80316-7. [DOI] [PubMed] [Google Scholar]
  155. Morrison SJ, Shah NM, Anderson DJ. Regulatory mechanisms in stem cell biology. Cell. 1997;88:287–298. doi: 10.1016/s0092-8674(00)81867-x. [DOI] [PubMed] [Google Scholar]
  156. Morrison SJ, Wandycz AM, Akashi K, Globerson A, Weissman IL. The aging of hematopoietic stem cells. Nat Med. 1996;2:1011–1016. doi: 10.1038/nm0996-1011. [DOI] [PubMed] [Google Scholar]
  157. Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilove J. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients–resultsof a phase I/II trial. Blood. 1997;89:3136–3147. [PubMed] [Google Scholar]
  158. Murray L, Chen B, Galy A, Chen S, Tushinski R, Uchida N, Negrin R, Tricot G, Jagannath S, Vesole D et al. (1995) Enrichment of human hematopoietic stem cell activity in the CD34 + Thy-1 + Lin-subpopulation from mobilized peripheral blood. Blood 85: 368–378. [PubMed]
  159. Nichols J. Introducing embryonic stem cells. Curr Biol. 2001;11:R503–R505. doi: 10.1016/s0960-9822(01)00304-9. [DOI] [PubMed] [Google Scholar]
  160. Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL, Kluin-Nelemans HC, Willemze R, Falkenburg JH. Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Exp Hematol. 2001;29:322–329. doi: 10.1016/s0301-472x(00)00669-x. [DOI] [PubMed] [Google Scholar]
  161. Nijmeijer BA, Willemze R, Falkenburg JH. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. Blood. 2002;100:654–660. doi: 10.1182/blood.v100.2.654. [DOI] [PubMed] [Google Scholar]
  162. Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. Stem Cells. 2001;19:193–204. doi: 10.1634/stemcells.19-3-193. [DOI] [PubMed] [Google Scholar]
  163. Okamoto R, Yajima T, Yamazaki M, Kanai T, Mukai M, Okamoto S, Ikeda Y, Hibi T, Inazawa J, Watanabe M. Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med. 2002;8:1011–1017. doi: 10.1038/nm755. [DOI] [PubMed] [Google Scholar]
  164. Oostendorp RA, Harvey KN, Kusadasi N, de Bruijn MF, Saris C, Ploemacher RE, Medvinsky AL, Dzierzak EA. Stromal cell lines from mouse aorta-gonads-mesonephros subregions are potent supporters of hematopoietic stem cell activity. Blood. 2002;99:1183–1189. doi: 10.1182/blood.v99.4.1183. [DOI] [PubMed] [Google Scholar]
  165. Orkin SH, Morrison SJ. Stem-cell competition. Nature. 2002;418:25–27. doi: 10.1038/418025a. [DOI] [PubMed] [Google Scholar]
  166. Orkin SH, Zon LI. Hematopoiesis and stem cells: Plasticity versus developmental heterogeneity. Nat Immunol. 2002;3:323–328. doi: 10.1038/ni0402-323. [DOI] [PubMed] [Google Scholar]
  167. Osawa M, Hanada K, Hamada H, Nakauchi H. Longterm lymphohematopoietic reconstitution by a single CD34–low/negative hematopoietic stem cell. Science. 1996;273:242–245. doi: 10.1126/science.273.5272.242. [DOI] [PubMed] [Google Scholar]
  168. Oscier DG. Myelodysplastic syndromes. Baillieres Clin Haematol. 1987;1:389–426. doi: 10.1016/s0950-3536(87)80007-0. [DOI] [PubMed] [Google Scholar]
  169. Palacios R, Golunski E, Samaridis J. In vitro generation of hematopoietic stem cells from an embryonic stem cell line. Proc Natl Acad Sci USA. 1995;92:7530–7534. doi: 10.1073/pnas.92.16.7530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA. 1993;90:9374–9378. doi: 10.1073/pnas.90.20.9374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. Papayannopoulou T, Priestley GV & Nakamoto B (1998) Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 91: 2231–2239. [PubMed]
  172. Papayannopoulou T, Priestley GV, Nakamoto B, Zafiropoulos V, Scott LM, Harlan JM. Synergistic mobilization of hemopoietic progenitor cells using concurrent beta1 and beta2 integrin blockade or beta2-deficient mice. Blood. 2001;97:1282–1288. doi: 10.1182/blood.v97.5.1282. [DOI] [PubMed] [Google Scholar]
  173. Pecora AL, Preti RA, Gleim GW, Jennis A, Zahos K, Cantwell S, Doria L, Isaacs R, Gillio AP, Michelis MA, Brochstein JA. CD34+CD33– cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. J Clin Oncol. 1998;16:2093–2104. doi: 10.1200/JCO.1998.16.6.2093. [DOI] [PubMed] [Google Scholar]
  174. Peschle C, Botta R, Muller R, Valtieri M, Ziegler BL. Purification and functional assay of pluripotent hematopoietic stem cells. Rev Clin Exp Hematol. 2001;5:3–14. doi: 10.1046/j.1468-0734.2001.00029.x. [DOI] [PubMed] [Google Scholar]
  175. Petzer AL, Zandstra PW, Piret JM, Eaves CJ. Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: Novel responses to Flt3-ligand and thrombopoietin. J Exp Med. 1996;183:2551–2558. doi: 10.1084/jem.183.6.2551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, Fagioli F, Berger M, Aglietta M. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood. 1997;89:2644–2653. [PubMed] [Google Scholar]
  177. Pilarski LM, Belch AR. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34(+) hematopoietic progenitors. Clin Cancer Res. 2002;8:3198–3204. [PubMed] [Google Scholar]
  178. Pilarski LM, Seeberger K, Coupland RW, Eshpeter A, Keats JJ, Taylor BJ, Belch AR. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol. 2002;30:221–228. doi: 10.1016/s0301-472x(01)00788-3. [DOI] [PubMed] [Google Scholar]
  179. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147. doi: 10.1126/science.284.5411.143. [DOI] [PubMed] [Google Scholar]
  180. Ploemacher RE. Characterisation and biology of normal human haematopoietic stem cells. Haematologica. 1999;84(SupplEHA4):4–7. [PubMed] [Google Scholar]
  181. Podesta M, Piaggio G, Frassoni F, Pitto A, Mordini N, Bregante S, Valeriani A, Bacigalupo A. Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:1011–1017. doi: 10.1038/sj.bmt.1700785. [DOI] [PubMed] [Google Scholar]
  182. Podesta M, Piaggio G, Frassoni F, Pitto A, Zikos P, Sessarego M, Abate M, Teresa Van Lint M, Berisso G, Bacigalupo A. The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. Blood. 1998;91:1959–1965. [PubMed] [Google Scholar]
  183. Potocnik AJ, Nielsen PJ, Eichmann K. In vitro generation of lymphoid precursors from embryonic stem cells. Embo J. 1994;13:5274–5283. doi: 10.1002/j.1460-2075.1994.tb06861.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, Shepherd V, Rowland A, Sirohi B, Tait D, Horton C, Long S, Singhal S. Allogeneic blood and bone-marrow stemcell transplantation in haematological malignant diseases: A randomised trial. Lancet. 2000;355:1231–1237. doi: 10.1016/S0140-6736(00)02090-0. [DOI] [PubMed] [Google Scholar]
  185. Pratt G, Rawstron AC, English AE, Johnson RJ, Jack AS, Morgan GJ, Smith GM. Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve. Br J Haematol. 2001;114:937–943. doi: 10.1046/j.1365-2141.2001.03027.x. [DOI] [PubMed] [Google Scholar]
  186. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71–74. doi: 10.1126/science.276.5309.71. [DOI] [PubMed] [Google Scholar]
  187. Prosper F, Stroncek D, Verfaillie CM. Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor. Blood. 1996;88:2033–2042. [PubMed] [Google Scholar]
  188. Punzel M, Gupta P, Roodell M, Mortari F, Verfaillie CM. Factor(s) secreted by AFT024 fetal liver cells following stimulation with human cytokines are important for human LTC-IC growth. Leukemia. 1999;13:1079–1084. doi: 10.1038/sj.leu.2401432. [DOI] [PubMed] [Google Scholar]
  189. Punzel M, Moore KA, Lemischka IR, Verfaillie CM. The type of stromal feeder used in limiting dilution assays influences frequency and maintenance assessment of human long-term culture initiating cells. Leukemia. 1999;13:92–97. doi: 10.1038/sj.leu.2401234. [DOI] [PubMed] [Google Scholar]
  190. Punzel M, Wissink SD, Miller JS, Moore KA, Lemischka IR, Verfaillie CM. The myeloid-lymphoid initiating cell (MLIC) assay assesses the fate of multipotent human progenitors in vitro. Blood. 1999;93:3750–3756. [PubMed] [Google Scholar]
  191. Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood. 2001;98:2615–2625. doi: 10.1182/blood.v98.9.2615. [DOI] [PubMed] [Google Scholar]
  192. Reyes M, Verfaillie CM. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci. 2001;938:231–233. doi: 10.1111/j.1749-6632.2001.tb03593.x. [DOI] [PubMed] [Google Scholar]
  193. Risau W, Sariola H, Zerwes HG, Sasse J, Ekblom P, Kemler R, Doetschman T. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development. 1988;102:471–478. doi: 10.1242/dev.102.3.471. [DOI] [PubMed] [Google Scholar]
  194. Robertson JA. Human embryonic stem cell research: Ethical and legal issues. Nat Rev Genet. 2001;2:74–78. doi: 10.1038/35047594. [DOI] [PubMed] [Google Scholar]
  195. Roeder I, Loeffler M. A novel dynamic model of hematopoietic stem cell organization based on the concept of within tissue plasticity. Exp Hematol. 2002;30:853–861. doi: 10.1016/s0301-472x(02)00832-9. [DOI] [PubMed] [Google Scholar]
  196. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, Berkowitz RL, Cabbad M, Dobrila NL, Taylor PE, Rosenfield RE, Stevens CE. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565–1577. doi: 10.1056/NEJM199811263392201. [DOI] [PubMed] [Google Scholar]
  197. Rufer N, Brummendorf TH, Chapuis B, Helg C, Lansdorp PM, Roosnek E. Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood. 2001;97:575–577. doi: 10.1182/blood.v97.2.575. [DOI] [PubMed] [Google Scholar]
  198. Rufer N, Brummendorf TH, Kolvraa S, Bischoff C, Christensen K, Wadsworth L, Schulzer M, Lansdorp PM. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med. 1999;190:157–167. doi: 10.1084/jem.190.2.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  199. Sanchez-Ramos JR. Neural cells derived from adult bone marrow and umbilical cord blood. J Neurosci Res. 2002;69:880–893. doi: 10.1002/jnr.10337. [DOI] [PubMed] [Google Scholar]
  200. Sato T, Laver JH, Ogawa M. Reversible expression of CD34 by murine hematopoietic stem cells. Blood. 1999;94:2548–2554. [PubMed] [Google Scholar]
  201. Schofield R. The relationship between the spleen colonyforming cell and the haemopoietic stem cell. Blood Cells. 1978;4:7–25. [PubMed] [Google Scholar]
  202. Shay JW. Accelerated telomere shortening in bone-marrow recipients. Lancet. 1998;351:153–154. doi: 10.1016/S0140-6736(05)78218-0. [DOI] [PubMed] [Google Scholar]
  203. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000;1:72–76. doi: 10.1038/35036093. [DOI] [PubMed] [Google Scholar]
  204. Shultz LD, Lang PA, Christianson SW, Gott B, Lyons B, Umeda S, Leiter E, Hesselton R, Wagar EJ, Leif JH, Kollet O, Lapidot T, Greiner DL. NOD/LtSz-Rag1null mice: An immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J Immunol. 2000;164:2496–2507. doi: 10.4049/jimmunol.164.5.2496. [DOI] [PubMed] [Google Scholar]
  205. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154:180–191. [PubMed] [Google Scholar]
  206. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A & Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756–763. [PubMed]
  207. Smith AG. Embryo-derived stem cells: Of mice and men. Annu Rev Cell Dev Biol. 2001;17:435–462. doi: 10.1146/annurev.cellbio.17.1.435. [DOI] [PubMed] [Google Scholar]
  208. Storb R, Yu C, Sandmaier BM, McSweeney PA, Georges G, Nash RA, Woolfrey A. Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting. Ann N Y Acad Sci. 1999;872:372–375. doi: 10.1111/j.1749-6632.1999.tb08481.x. [DOI] [PubMed] [Google Scholar]
  209. Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood. 1989;74:1563–1570. [PubMed] [Google Scholar]
  210. Szilvassy SJ, Meyerrose TE, Grimes B. Effects of cell cycle activation on the short-term engraftment properties of ex vivo expanded murine hematopoietic cells. Blood. 2000;95:2829–2837. [PubMed] [Google Scholar]
  211. Tabbara IA, Zimmerman K, Morgan C, Nahleh Z. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med. 2002;162:1558–1566. doi: 10.1001/archinte.162.14.1558. [DOI] [PubMed] [Google Scholar]
  212. Takeuchi M, Sekiguchi T, Hara T, Kinoshita T, Miyajima A. Cultivation of aorta-gonad-mesonephros-derived hematopoietic stem cells in the fetal liver microenvironment amplifies longterm repopulating activity and enhances engraftment to the bone marrow. Blood. 2002;99:1190–1196. doi: 10.1182/blood.v99.4.1190. [DOI] [PubMed] [Google Scholar]
  213. Terada N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, Meyer EM, Morel L, Petersen BE, Scott EW. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature. 2002;416:542–545. doi: 10.1038/nature730. [DOI] [PubMed] [Google Scholar]
  214. Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38– progenitor cells. Blood. 1991;77:1218–1227. [PubMed] [Google Scholar]
  215. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–1147. doi: 10.1126/science.282.5391.1145. [DOI] [PubMed] [Google Scholar]
  216. Thomson JA, Marshall VS. Primate embryonic stem cells. Curr Top Dev Biol. 1998;38:133–165. doi: 10.1016/S0070-2153(08)60246-X. [DOI] [PubMed] [Google Scholar]
  217. Thornley I, Sutherland DR, Nayar R, Sung L, Freedman MH, Messner HA. Replicative stress after allogeneic bone marrow transplantation: changes in cycling of CD34+CD90+ and CD34+CD90– hematopoietic progenitors. Blood. 2001;97:1876–1878. doi: 10.1182/blood.v97.6.1876. [DOI] [PubMed] [Google Scholar]
  218. Tisdale JF & Wilson DR (eds) (2002) Clinical applications of gene therapy. Current Opinion in Molecular Therapeutics, 4: 409–534. [PubMed]
  219. Traycoff CM, Hoffman R, Zanjani ED, Cornetta K, Law P, Gianni AM, Bregni M, Siena S, Abboud MR, Laver J, et al. Measurement of marrow repopulating potential of human hematopoietic progenitor and stem cells using a fetal sheep model. Prog Clin Biol Res. 1994;389:281–291. [PubMed] [Google Scholar]
  220. Tsai RY, Kittappa R, McKay RD. Plasticity, niches, and the use of stem cells. Dev Cell. 2002;2:707–712. doi: 10.1016/s1534-5807(02)00195-8. [DOI] [PubMed] [Google Scholar]
  221. Turner CW, Yeager AM, Waller EK, Wingard JR, Fleming WH. Engraftment potential of different sources of human hematopoietic progenitor cells in BNX Mice. Blood. 1996;87:3237–3244. [PubMed] [Google Scholar]
  222. Ueda T, Yoshino H, Kobayashi K, Kawahata M, Ebihara Y, Ito M, Asano S, Nakahata T, Tsuji K. Hematopoietic repopulating ability of cord blood CD34(+) cells in NOD/Shi-scid mice. Stem Cells. 2000;18:204–213. doi: 10.1634/stemcells.18-3-204. [DOI] [PubMed] [Google Scholar]
  223. Van Den Berg DJ, Sharma AK, Bruno E, Hoffman R. Role of members of the Wnt gene family in human hematopoiesis. Blood. 1998;92:3189–3202. [PubMed] [Google Scholar]
  224. Vassiliou G, Amrolia P, Roberts IA. Allogeneic transplantation for haemoglobinopathies. Best Pract Res Clin Haematol. 2001;14:807–822. doi: 10.1053/beha.2001.0174. [DOI] [PubMed] [Google Scholar]
  225. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA. 1994;91:9857–9860. doi: 10.1073/pnas.91.21.9857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  226. Verfaillie CM, Almeida-Porada G, Wissink S, Zanjani ED. Kinetics of engraftment of CD34(–) and CD34(+) cells from mobilized blood differs from that of CD34(–) and CD34(+) cells from bone marrow. Exp Hematol. 2000;28:1071–1079. doi: 10.1016/s0301-472x(00)00506-3. [DOI] [PubMed] [Google Scholar]
  227. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science. 2002;297:2256–2259. doi: 10.1126/science.1074807. [DOI] [PubMed] [Google Scholar]
  228. Wang JC, Lapidot T, Cashman JD, Doedens M, Addy L, Sutherland DR, Nayar R., Laraya P, Minden M, Keating A, Eaves AC, Eaves CJ, Dick JE. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998;91:2406–2414. [PubMed] [Google Scholar]
  229. Weaver A, Ryder D, Crowther D, Dexter TM, Testa NG. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colonystimulating factor. Blood. 1996;88:3323–3328. [PubMed] [Google Scholar]
  230. Wiles MV, Keller G. Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture. Development. 1991;111:259–267. doi: 10.1242/dev.111.2.259. [DOI] [PubMed] [Google Scholar]
  231. Woods NB, Ooka A, Karlsson S. Development of gene therapy for hematopoietic stem cells using lentiviral vectors. Leukemia. 2002;16:563–569. doi: 10.1038/sj.leu.2402447. [DOI] [PubMed] [Google Scholar]
  232. Wynn R, Thornley I, Freedman M, Saunders EF. Telomere shortening in leucocyte subsets of long-term survivors of allogeneic bone marrow transplantation. Br J Haematol. 1999;105:997–1001. doi: 10.1046/j.1365-2141.1999.01450.x. [DOI] [PubMed] [Google Scholar]
  233. Wynn RF, Cross MA, Hatton C, Will AM, Lashford LS, Dexter TM, Testa NG. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 1998;351:178–181. doi: 10.1016/S0140-6736(97)08256-1. [DOI] [PubMed] [Google Scholar]
  234. Yamashita J, Itoh H, Hirashima M, Ogawa M, Nishikawa S, Yurugi T, Naito M, Nakao K. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature. 2000;408:92–96. doi: 10.1038/35040568. [DOI] [PubMed] [Google Scholar]
  235. Yan XQ, Hartley C, McElroy P, Chang A, McCrea C, McNiece I. Peripheral blood progenitor cells mobilized by recombinant human granulocyte colony-stimulating factor plus recombinant rat stem cell factor contain long-term engrafting cells capable of cellular proliferation for more than two years as shown by serial transplantation in mice. Blood. 1995;85:2303–2307. [PubMed] [Google Scholar]
  236. Ying QL, Nichols J, Evans EP, Smith AG. Changing potency by spontaneous fusion. Nature. 2002;416:545–548. doi: 10.1038/nature729. [DOI] [PubMed] [Google Scholar]
  237. Zanjani ED, Ascensao JL, Flake AW, Harrison MR, Tavassoli M. The fetus as an optimal donor and recipient of hemopoietic stem cells. Bone Marrow Transplant. 1992;10:107–114. [PubMed] [Google Scholar]
  238. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7:1028–1034. doi: 10.1038/nm0901-1028. [DOI] [PubMed] [Google Scholar]
  239. Ziegler BL, Valtieri M, Porada GA, De Maria R, Muller R, Masella B, Gabbianelli M, Casella I, Pelosi E, Bock T, Zanjani ED, Peschle C. KDR receptor: A key marker defining hematopoietic stem cells. Science. 1999;285:1553–1558. doi: 10.1126/science.285.5433.1553. [DOI] [PubMed] [Google Scholar]
  240. Zon LI. Developmental biology of hematopoiesis. Blood. 1995;86:2876–2891. [PubMed] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES